Dapagliflozin alleviates myocardial ischemia/reperfusion injury by reducing ferroptosis via MAPK signaling inhibition

Reperfusion is essential for ischemic myocardium but paradoxically leads to myocardial damage that worsens cardiac functions. Ferroptosis often occurs in cardiomyocytes during ischemia/reperfusion (I/R). The SGLT2 inhibitor dapagliflozin (DAPA) exerts cardioprotective effects independent of hypoglyc...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Weixiang Chen, Yue Zhang, Zuoxiang Wang, Mingyue Tan, Jia Lin, Xiaodong Qian, Hongxia Li, Tingbo Jiang
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2023-02-01
Serie:	Frontiers in Pharmacology
Soggetti:	myocardial ischemia/reperfusion dapagliflozin ferroptosis MAPK pathway treatment
Accesso online:	https://www.frontiersin.org/articles/10.3389/fphar.2023.1078205/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!